Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 4:16:1584450.
doi: 10.3389/fimmu.2025.1584450. eCollection 2025.

Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights

Yi Zhang  1 , Shasha Jiang  1 , Jing Lv  1 , Wei Feng  1 , Yan Yu  1 , Heping Zhao  1
Affiliations
Review

Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights

Yi Zhang et al. Front Immunol. .

Abstract

Recent advances in immunotherapy have shown remarkable success across multiple solid tumor types, revitalizing interest in immune-modulating strategies for osteosarcoma (OS). Within the complex tumor microenvironment (TME), immune cells exhibit dual regulatory roles-exerting critical regulatory influences on both tumorigenesis and disease progression while simultaneously serving as therapeutic targets. Particularly in OS, the dynamic interplay between malignant cells and the unique bone microenvironment manifests through intricate immune cell-mediated crosstalk. This comprehensive review analyzes the paradoxical roles of immune cell subsets in OS pathophysiology, detailing their tumor-promoting versus tumor-suppressing functions. Furthermore, we systematically evaluate recent progress in immune cell-targeted therapeutic approaches, including adoptive cell therapies and macrophage reprogramming strategies. The review encompasses current clinical applications and emerging preclinical innovations, providing valuable insights for optimizing immunotherapeutic approaches in OS management.

Keywords: immune cell; immunotherapy; osteosarcoma; tumor microenvironment; tumor-associated macrophages.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The immunosuppressive microenvironment of OS.
Figure 2
Figure 2
The tumor-promoting role of TAMs in OS.
Figure 3
Figure 3
Immune therapy strategies based on immune cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Whelan J, McTiernan A, Cooper N, Wong YK, Francis M, Vernon S, et al. Incidence and survival of Malignant bone sarcomas in England 1979-2007. Int J Cancer. (2012) 131:E508–17. doi: 10.1002/ijc.26426 - DOI - PubMed
    1. Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. (2019) 109:36–50. doi: 10.1016/j.ejca.2018.11.027 - DOI - PMC - PubMed
    1. Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol. (2015) 26:407–14. doi: 10.1093/annonc/mdu526 - DOI - PMC - PubMed
    1. Sadykova LR, Ntekim AI, Muyangwa-Semenova M, Rutland CS, Jeyapalan JN, Blatt N, et al. Epidemiology and risk factors of osteosarcoma. Cancer Invest. (2020) 38:259–69. doi: 10.1080/07357907.2020.1768401 - DOI - PubMed
    1. Mailankody S, Kumar VS, Khan SA, Banavali SD, Bajpai J. Resource-appropriate selection of osteosarcoma treatment protocols in low- and middle-income countries. Pediatr Blood Cancer. (2022) 69:e29540. doi: 10.1002/pbc.29540 - DOI - PubMed

LinkOut - more resources